| __timestamp | Gilead Sciences, Inc. | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 44820000 |
| Thursday, January 1, 2015 | 3426000000 | 82080000 |
| Friday, January 1, 2016 | 3398000000 | 97130000 |
| Sunday, January 1, 2017 | 3878000000 | 121271000 |
| Monday, January 1, 2018 | 4056000000 | 153548000 |
| Tuesday, January 1, 2019 | 4381000000 | 202541000 |
| Wednesday, January 1, 2020 | 5151000000 | 245164000 |
| Friday, January 1, 2021 | 5246000000 | 285773000 |
| Saturday, January 1, 2022 | 5673000000 | 325998000 |
| Sunday, January 1, 2023 | 6090000000 | 332540000 |
| Monday, January 1, 2024 | 6091000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial. From 2014 to 2023, Gilead Sciences, Inc. and PTC Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Gilead Sciences, a major player, has seen its SG&A expenses grow by over 100%, from approximately $3 billion in 2014 to $6 billion in 2023. This reflects its expansive market strategies and robust operational scale. In contrast, PTC Therapeutics, a smaller biotech firm, increased its SG&A spending by over 600%, from $45 million to $332 million in the same period, indicating aggressive growth and investment in market penetration. These trends highlight the contrasting strategies of a pharmaceutical giant and an emerging biotech firm, offering insights into their operational priorities and market positioning.
Selling, General, and Administrative Costs: Johnson & Johnson vs Gilead Sciences, Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
Gilead Sciences, Inc. vs Novavax, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs PTC Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.
PTC Therapeutics, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.